Everest Medicines (HKG: 1952) today unveiled its 2030 strategy. Following the announcement, the Company’s shares strengthened during the trading session and briefly reached an intraday high of HKD 48.54. By…
Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (Everest Medicines China), has entered into two strategic agreements with privately held Hasten Biopharmaceutical…
Since 2025, driven by both policy tailwinds and fundamental strengths, the innovative drug sector in the Hong Kong stock market has experienced a valuation recovery. Although it experienced some correction…
Enterprise platform, queried through natural language, to help pharma, biotech, and investors make better decisions. High-quality biological patient data, enriched and integrated for use by AI agents. Owkin today announces…
AGFA HealthCare has been recognized by KLAS Research for significant satisfaction gains. Customer satisfaction with AGFA’s Enterprise Imaging VNA and XERO® Viewer has increased significantly over the past 18 months,…
Kangji Medical Holdings Limited (Kangji Medical or the Company, HKG: 9997) and Knight Bidco Limited (the Offeror) today announced that a circular in relation to the proposed privatisation of Kangji…
Everest Medicines (HKG:1952) today announced that it has acquired an exclusive license with Visara, Inc. (Visara), a subsidiary of NovaBridge Biosciences (formally known as I-Mab, and is a company listed…
Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen Cancer Vaccine EVM14 at NEXT Oncology Virginia…
Hong Kong Department of Health accepts NDA for dorzagliatin, the world’s first approved glucokinase activator (GKA). Builds on China approval and strong Phase III and real-world clinical results showing durable…
On August 29, Everest Medicines (HKG: 1952) announced its interim results for the six months ended June 30, 2025. The Company’s total revenue for the first half of 2025 reached…
ADC pipeline with multiple products entering key clinical stages Revenue increased by 350% year-on-year Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma…
In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a…
– Sales of Innovative Products Up by 27.2% Year-on-Year to RMB7.8 Billion – Profit Attributable to Owners of the Parent from Continuing Operations Surges 140.2% – Continues R&D Investment Speeds…
Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the “Updated Guidelines”). Etrasimod, an S1P receptor modulator, is recommended…
Everest Medicines (HKG: 1952.HK, Everest) today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of…
Essex Bio-Technology Limited (Essex or the Group, HKG: 1061) is pleased to announce that a Biologics License Application (BLA) for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has…
Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the…
Everest Medicines (HKG: 1952) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R). NEFECON(R) is indicated to reduce the loss of kidney function…
Everest Medicines (HKG: 1952) today announced that the supplemental application for the production expansion of NEFECON® has been officially approved by China’s National Medical Products Administration (NMPA). This approval for…
Everest Medicines (HKG: 1952) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash. Upon completion…
